How much profit has Amplia Therapeutics made this year?
Amplia Therapeutics has made -4.5 M AUD this year.
Amplia Therapeutics Net Income 2024
Amplia Therapeutics Net Income
-4.5 M AUD
Ticker
ATX.AX
ISIN
AU0000023822
WKN
A2N5RL
In 2024, Amplia Therapeutics's profit amounted to -4.5 M AUD, a -27.86% increase from the -6.24 M AUD profit recorded in the previous year.
The Amplia Therapeutics Net Income history
| YEAR | NET INCOME (undefined AUD) |
|---|---|
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
Amplia Therapeutics Revenue, EBIT, Net Income AU0000023822 · A2N5RL
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Amplia Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amplia Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amplia Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Amplia Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Amplia Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Amplia Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amplia Therapeutics’s growth potential.
Amplia Therapeutics Revenue, EBIT and net profit per share
| Date | Amplia Therapeutics Revenue | Amplia Therapeutics EBIT | Amplia Therapeutics Net Income |
|---|---|---|---|
| 2024 | 4.44 M undefined | -4.59 M undefined | -4.5 M undefined |
| 2023 | 1.15 M undefined | -6.33 M undefined | -6.24 M undefined |
| 2022 | 1.98 M undefined | -3.64 M undefined | -3.64 M undefined |
| 2021 | 1.53 M undefined | -2.34 M undefined | -2.28 M undefined |
| 2020 | 34,230 undefined | -2.22 M undefined | -2.22 M undefined |
| 2019 | 50,470 undefined | -1.89 M undefined | -1.87 M undefined |
| 2018 | 642,840 undefined | -4.32 M undefined | -4.3 M undefined |
| 2017 | 1.83 M undefined | -7.14 M undefined | -7.08 M undefined |
| 2016 | 2.29 M undefined | -5.02 M undefined | -4.94 M undefined |
| 2015 | 30,310 undefined | -5.4 M undefined | -5.24 M undefined |
| 2014 | 30,000 undefined | -4.06 M undefined | -4.5 M undefined |
| 2013 | 250,000 undefined | -3.03 M undefined | -3.39 M undefined |
| 2012 | 610,000 undefined | -2.85 M undefined | -3.25 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2012 | 610,000 AUD | -2.85 M AUD | -3.25 M AUD |
| 2013 | 250,000 AUD | -3.03 M AUD | -3.39 M AUD |
| 2014 | 30,000 AUD | -4.06 M AUD | -4.5 M AUD |
| 2015 | 30,310 AUD | -5.4 M AUD | -5.24 M AUD |
| 2016 | 2.29 M AUD | -5.02 M AUD | -4.94 M AUD |
| 2017 | 1.83 M AUD | -7.14 M AUD | -7.08 M AUD |
| 2018 | 642,840 AUD | -4.32 M AUD | -4.3 M AUD |
| 2019 | 50,470 AUD | -1.89 M AUD | -1.87 M AUD |
| 2020 | 34,230 AUD | -2.22 M AUD | -2.22 M AUD |
| 2021 | 1.53 M AUD | -2.34 M AUD | -2.28 M AUD |
| 2022 | 1.98 M AUD | -3.64 M AUD | -3.64 M AUD |
| 2023 | 1.15 M AUD | -6.33 M AUD | -6.24 M AUD |
| 2024 | 4.44 M AUD | -4.59 M AUD | -4.5 M AUD |
Amplia Therapeutics stock margins AU0000023822 · A2N5RL
The Amplia Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amplia Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amplia Therapeutics.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Amplia Therapeutics's sales revenue. A higher gross margin percentage indicates that the Amplia Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Amplia Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Amplia Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amplia Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amplia Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amplia Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Amplia Therapeutics Margin History
| Amplia Therapeutics Gross margin | Amplia Therapeutics Profit margin | Amplia Therapeutics EBIT margin | Amplia Therapeutics Profit margin |
|---|---|---|---|
| 2024 | 76.8 % | -103.32 % | -101.48 % |
| 2023 | 76.8 % | -550.92 % | -543.56 % |
| 2022 | 92.02 % | -183.72 % | -183.74 % |
| 2021 | 76.8 % | -152.6 % | -148.75 % |
| 2020 | 76.8 % | -6,494.86 % | -6,483.99 % |
| 2019 | 76.8 % | -3,745.29 % | -3,705.09 % |
| 2018 | 76.8 % | -672.73 % | -668.53 % |
| 2017 | 76.8 % | -389.75 % | -386.41 % |
| 2016 | 76.8 % | -218.64 % | -215.41 % |
| 2015 | 76.8 % | -17,810.1 % | -17,276.74 % |
| 2014 | 76.8 % | -13,533.33 % | -15,000 % |
| 2013 | 76.8 % | -1,212 % | -1,356 % |
| 2012 | 76.8 % | -467.21 % | -532.79 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2012 | 76.8 % | -467.21 % | -532.79 % |
| 2013 | 76.8 % | -1,212 % | -1,356 % |
| 2014 | 76.8 % | -13,533.33 % | -15,000 % |
| 2015 | 76.8 % | -17,810.1 % | -17,276.74 % |
| 2016 | 76.8 % | -218.64 % | -215.41 % |
| 2017 | 76.8 % | -389.75 % | -386.41 % |
| 2018 | 76.8 % | -672.73 % | -668.53 % |
| 2019 | 76.8 % | -3,745.29 % | -3,705.09 % |
| 2020 | 76.8 % | -6,494.86 % | -6,483.99 % |
| 2021 | 76.8 % | -152.6 % | -148.75 % |
| 2022 | 92.02 % | -183.72 % | -183.74 % |
| 2023 | 76.8 % | -550.92 % | -543.56 % |
| 2024 | 76.8 % | -103.32 % | -101.48 % |
Amplia Therapeutics Aktienanalyse
What does Amplia Therapeutics do?
Amplia Therapeutics Ltd was originally founded in 2012 and is based in Sydney, Australia. The company focuses on the development of novel therapies for cancer and other serious diseases. Amplia's main focus is on the development of peptide-based therapeutics, which are polypeptides derived from naturally occurring proteins. The company also places special emphasis on non-coding RNA (ncRNA) research and is working on the discovery, development, and commercialization of drugs that specifically target ncRNA. Amplia already holds various patents and approvals in this field. Amplia's core business is the research and development of drugs for cancer. The company collaborates with academic research groups and institutions worldwide and works closely with manufacturers of synthetic peptides to ensure high quality and efficacy in drug production. Amplia has developed various drug platforms to support its research activities. One of these platforms is the peptide library, which contains a large collection of synthetic peptides that can be used against different types of cancer. Another platform is ncRNA-based therapeutics, which exert their effects by inhibiting ncRNA molecules. Currently, Amplia Therapeutics has several drugs in various stages of clinical development. One example is AMP945, a peptide designed as a potential medication for triple-negative breast cancer. The drug targets a protein receptor found on the surface of cancer cells and has shown promising results in inhibiting tumor growth in animal models. Another example is ATX101, an ncRNA inhibitor also being developed as a potential medication for cancer. The inhibitor targets a specific form of ncRNA molecule that is overproduced in various types of cancer. In animal models, the drug has shown promising results in preventing tumor progression. Overall, Amplia Therapeutics Ltd aims to develop drugs that can significantly improve the lives of patients. The company strives to set new standards in cancer therapy and continuously works to improve its technology platforms and expand its product pipeline. Amplia Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Amplia Therapeutics's Profit Margins
The profit margins of Amplia Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Amplia Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Amplia Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Amplia Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Amplia Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Amplia Therapeutics stock
How has the profit developed compared to last year?
The profit has increased by -27.86% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Amplia Therapeutics publish its earnings?
Amplia Therapeutics publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Amplia Therapeutics?
The profits of Amplia Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Amplia Therapeutics?
You can learn more about the earnings of Amplia Therapeutics by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Amplia Therapeutics pay?
Over the past 12 months, Amplia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amplia Therapeutics is expected to pay a dividend of 0 AUD.
What is the dividend yield of Amplia Therapeutics?
The current dividend yield of Amplia Therapeutics is .
When does Amplia Therapeutics pay dividends?
Amplia Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Amplia Therapeutics?
Amplia Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Amplia Therapeutics?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Amplia Therapeutics located?
Amplia Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Amplia Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Amplia Therapeutics from 7/7/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 7/7/2024.
When did Amplia Therapeutics pay the last dividend?
The last dividend was paid out on 7/7/2024.
What was the dividend of Amplia Therapeutics in the year 2023?
In the year 2023, Amplia Therapeutics distributed 0 AUD as dividends.
In which currency does Amplia Therapeutics pay out the dividend?
The dividends of Amplia Therapeutics are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Amplia Therapeutics
Our stock analysis for Amplia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amplia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Amplia Therapeutics Revenue
- Amplia Therapeutics Net Income
- Amplia Therapeutics P/E
- Amplia Therapeutics P/S
- Amplia Therapeutics EBIT
- Amplia Therapeutics Dividend
- Amplia Therapeutics Stocks
- Amplia Therapeutics Market capitalization
- Amplia Therapeutics Debt
- Amplia Therapeutics Liabilities
- Amplia Therapeutics Equity
- Amplia Therapeutics AAQS
- Amplia Therapeutics Employees
- Amplia Therapeutics ROE
- Amplia Therapeutics ROA
- Amplia Therapeutics ROCE
